Viking Therapeutics, Inc. (LON:0VQA)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.42B -21.4% |
| Revenue (ttm) | n/a |
| Net Income | -267.21M |
| EPS | -2.37 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,265 |
| Average Volume | 15,291 |
| Open | 30.92 |
| Previous Close | 27.28 |
| Day's Range | 30.45 - 34.44 |
| 52-Week Range | 18.93 - 59.06 |
| Beta | 0.70 |
| RSI | 39.52 |
| Earnings Date | Feb 11, 2026 |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ... [Read more]
News
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short
Viking Therapeutics, Inc. aces hurdles for obesity drug VK2735 vs. Zepbound/Wegovy—tolerability, weak differentiation, and competition. Click for this VKTX update.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmac...
The Smartest Growth Stock to Buy With $30 Right Now
The recent success of Novo Nordisk and Eli Lilly validates a potential $150 billion obesity drug market. Viking Therapeutics is a year or two from launching a drug that can compete with industry leade...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
2 Biotech Stocks Set to Rebound in 2026
Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the ...
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?
Both companies may succeed in this industry.
3 Growth Stocks to Invest $1,000 in Right Now
Shares of SoundHound AI have been all over the place of late, but that extreme volatility appears to have run its course. Viking Therapeutics wasn't the first name to the weight loss drug party.
The Best Stocks to Invest $40 in to Start the New Year Off Right
Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may benefit from this market in just a few years.
Tema Heart & Health ETF Buys 5,473 Shares of Viking Therapeutics Inc (VKTX)
Tema Heart & Health ETF Buys 5,473 Shares of Viking Therapeutics Inc (VKTX)
Prime Capital Investment Advisors, LLC Buys 5,825 Shares of Viking Therapeutics Inc (VKTX)
Prime Capital Investment Advisors, LLC Buys 5,825 Shares of Viking Therapeutics Inc (VKTX)
2 Bargain Stocks You Can Buy for Less Than $100 Right Now
Viking Therapeutics doesn't have any approved products in its portfolio, but VK2735 has shown encouraging weight loss results in clinical trials. PayPal's growth has been poor in recent quarters, but ...
1 Stock That Could Soar by 175%, According to Wall Street
Viking Therapeutics' price target implies a juicy upside from its current levels. The stock's most important catalysts will likely have to wait until next year.
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026?
Despite a challenging year, the company has a lot to look forward to in the coming years.
HARBOR CAPITAL ADVISORS, INC. Buys 600 Shares of Viking Therapeutics Inc (VKTX)
HARBOR CAPITAL ADVISORS, INC. Buys 600 Shares of Viking Therapeutics Inc (VKTX)
VKTX Crosses Below Key Moving Average Level
In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) crossed below their 200 day moving average of $30.56, changing hands as low as $29.54 per share. Viking Therapeutics Inc shares ...
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viking Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Viking Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Appetite for weight-loss deals broader than visible, Viking CEO says
Weight-loss drug developer Viking Therapeutics CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as drugmakers seek to tap into the potential $150 billio...
Notable Monday Option Activity: VKTX, UAL, AGYS
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Viking Therapeutics Inc (Symbol: VKTX), where a total volume of 12,410 contracts h...
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program ...
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale
This clinical-stage biotech developing metabolic therapies reported a notable insider sale amid a challenging year for its stock.
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.
Lightning Round: QXO is a buy, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: QXO, Viking Therapeutics, and Starfighters Space.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiven...